Shots: The BORA P-III trial involves assessing of Fasenra (benralizumab) enrolling patients in ratio (1:1) who have completed one of the two SIROCCO or CALIMA P-III trials, administering Fasenra 30 […]readmore
Tags : reports
Shots: Results: ESTEEM 1, 2: NAPSI@32wk (31.3% vs 15.5), DLQI @16wks. (28.7% vs 8.1%); UNVEIL: NAPSI@32wks. (36.2% vs 37.2%), DLQI@16wks. (23.7% vs 10.6%) Though, Post-hoc analysis revealed that OTEZLA was […]readmore
Shots: The survey enrolled 300 (US respondents) psoriasis patients are interested in additional benefits i.e. no. of years of proven efficacy and safety with no injection site reactions in addition […]readmore
Shots: FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients, intolerant to bDMARDs FINCH-2 results (N= ≥153): ACR20@12wk (66 […]readmore
Shots: Study involves assessing of inhaled TLR9 agonist with anti-PD-1 in mouse preclinical model, leading a long term survival in two different mouse lung tumour models Administration of SD-101 in […]readmore